COVID-19 pandemic: Guidance for Add-Aspirin participants
In the current pandemic situation, we know that trial participants may have concerns or questions about taking their trial treatment and attending follow-up appointments. We have provided some general guidance here.
Add-Aspirin
Can taking daily aspirin after treatment for cancer stop or delay the cancer from coming back?
Welcome to Add-Aspirin
This website is designed to provide information about the Add-Aspirin Trial, both for people taking part in the trial (participants) and collaborators. Please use the menus at the top of the screen to find out more about the trial.
Add-Aspirin is a large randomised clinical trial, which is taking place in the UK, Republic of Ireland and India. It will recruit 11,000 participants to help find out whether regular aspirin use after treatment for an early stage cancer can prevent the cancer from coming back and preventing deaths.
Congratulations to our top 5 recruiting centres:
- Tata Memorial Hospital, Mumbai
- University Hospital Coventry & Warwickshire
- Western General Hospital
- Worcestershire Royal Hospital
- Royal Lancaster Infirmary
*FOR GENERAL AND CLINICAL QUERIES, PLEASE CHECK OUR FAQs*
News
New Participant Information Video
To find out more about the Add-Aspirin clinical trial, please watch our video. This video is for UK patients only.
A notice for Participants in the Add-Aspirin Breast Cohort
Please read this message from the the Add-Aspirin team.
Guidance on COVID-19 Vaccination
Please read guidance from our Trial Management Group on having a COVID-19 vaccine whilst participating in Add-Aspirin.
Quick Links
From Monday 16th March 2020, to RANDOMISE a participant from the UK please call +44 (0)20 7670 4925, rather than the usual randomisation line.
To RANDOMISE a participant from Republic of Ireland or India only, please use the 'Register a participant' link above to randomise online. Please make sure to press 'Randomise' once logged in to the server.
We have been experiencing intermittent issues with the trial websites. In the event of an emergency unblinding outside of office hours (including over the Easter bank holidays), if the usual unblinding links are not working, please telephone +(0)20 7670 4906 or +(0)20 7670 4892 to reach one of the Trial Managers.
Unblind a participant in the UK
Breast
We aim to recruit 3100 individuals who have had surgery to remove an early stage breast cancer.
CURRENT RECRUITMENT STATUS:
OPEN
Detailed eligibility criteria available here
Top recruiters: Tata Memorial Hospital Mumbai, Western General Hospital, Worcestershire Royal Hospital, Churchill Hospital Oxford
PARTICIPANTS REGISTERED: 4220
PARTICIPANTS RANDOMISED: 3603
Colon/Rectum
We aim to to recruit 2600 individuals who have had surgery to remove an early stage bowel cancer.
CURRENT RECRUITMENT STATUS:
OPEN
Detailed eligibility criteria available here
Top recruiters: Western General Hospital, St James's University Hospital, Bristol Haematology & Oncology Centre, George Eliot Hospital
PARTICIPANTS REGISTERED: 2723
PARTICIPANTS RANDOMISED: 2264
Gastro
We aim to recruit 2100 individuals who have had surgery or a combination of chemotherapy and radiotherapy to treat a cancer of the stomach or oesophagus (food pipe).
CURRENT RECRUITMENT STATUS: OPEN
Detailed eligibility criteria available here
Top recruiters: Tata Memorial Hospital Mumbai, Cancer Institute (WIA), Basavatarakam Indo-American Cancer Hospital & Research Institute, Christie Hospital
PARTICIPANTS REGISTERED: 705
PARTICIPANTS RANDOMISED: 567
Prostate
We aim to recruit 2120 individuals who have had surgery or radiotherapy to treat an early stage prostate cancer.
CURRENT RECRUITMENT STATUS:
OPEN
Detailed eligibility criteria available here
Top recruiters: University Hospital Coventry & Warwickshire, Darent Valley Hospital, University Hospital of Wales, Queen Elizabeth Hospital King's Lynn
PARTICIPANTS REGISTERED: 2074
PARTICIPANTS RANDOMISED: 1790
the trial is being jointly funded by
